254751-08-1

Usage

Uses

Used in Pharmaceutical Research and Development:
Acetic acid, 2-[[2-(1,1-dimethylethyl)phenyl]amino]-2-oxo-, is used as a research compound for the development of new drugs and pharmaceutical products. Its unique chemical structure and potential medicinal properties make it a valuable candidate for further study and application in the pharmaceutical industry.
Used in Drug Production:
Acetic acid, 2-[[2-(1,1-diMethylethyl)phenyl]aMino]-2-oxois also used in the production of various drugs and pharmaceutical products. Its versatility and potential therapeutic uses make it a valuable ingredient in the formulation of medications for the treatment of different diseases and conditions.
Used in Medicinal Applications:
Acetic acid, 2-[[2-(1,1-dimethylethyl)phenyl]amino]-2-oxo-, is used as a medicinal compound for the treatment of various diseases and conditions. Its potential therapeutic uses are being widely studied, and it may offer new avenues for treatment and management of various health issues.

Upstream product

• 483334-60-7 methyl 2-[N-(2-tert-butylphenylamino)]-2-oxoacetate 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 959508-79-3 ethyl 2-(2-tert-butylanilino)-2-oxo-acetate 

Downstream Products

• 254750-82-8 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 

Relevant academic research and scientific papers

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease

A series of caspase inhibitors containing γ-amino acid moiety have been synthesized. A systemic study on their structure-activity relationship of anti-apoptotic cellular activity is presented. These efforts led to the discovery of compound 20o as a potent caspase inhibitor, which demonstrated preclinical ameliorating total bilirubin efficacy with a significantly improved pharmacokinetic profile.

METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE

Provided herein are methods and compositions for treatment of an elevated MELD score or Child-Pugh score or their components by administering a of a caspase inhibitor alone or in combination with current treatments for liver disease.

TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions

First-in-class pan caspase inhibitor developed for the treatment of liver disease

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.

C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases

This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients su